Received Jul 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 3 | — | — |
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | 2 | — | — |
Hypersensitivity rxns; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (Hypersensitivity rxns) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. Co-suspect product included non-company product COVID-19 vaccine for an unknown indication. No Medical History information was reported. In 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient received first dose of COVID-19 vaccine (unknown route) 1 dosage form. On an unknown date, received second dose of COVID-19 vaccine (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HYPERSENSITIVITY (Hypersensitivity rxns). At the time of the report, HYPERSENSITIVITY (Hypersensitivity rxns) outcome was unknown. Concomitant medication was not provided. Patient took the vaccine 3.25 year ago. It was reported that the patient had experienced hypersensitivity reactions following her initial two doses and even more so after receiving a Moderna COVID-19 booster. It was told to the pharmacist upon arrival of patient severe reaction to mRNA vaccines was reported. Treatment information was not reported.